Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;25(12):374-379.
doi: 10.1007/s11894-023-00905-5. Epub 2023 Nov 9.

Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus

Shawn L Shah  1 , Kerry Dunbar  2
Affiliations
Review

Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus

Shawn L Shah et al. Curr Gastroenterol Rep. 2023 Dec.

Abstract

Purpose of review: Barrett's esophagus (BE) is associated with chronic gastroesophageal reflux disease and is a known precursor to esophageal adenocarcinoma. While endoscopic surveillance strategies and the role for endoscopic eradication therapy have been well established, there has been much interest in identifying chemopreventive agents to disrupt or halt the metaplasia-dysplasia-carcinoma sequence in patients with BE.

Recent findings: No pharmacological agent has held more hope in reducing the risk of neoplastic progression in BE than proton pump inhibitors (PPIs). However, data supporting PPIs for chemoprevention have largely been from observational cohort and case-control studies with mixed results. In this review, we revisit the literature and highlight the role of PPIs in patients with BE as it pertains to chemoprophylaxis against the progression of BE to dysplasia and esophageal adenocarcinoma.

Keywords: Barrett’s esophagus; Chemoprophylaxis; Esophageal adenocarcinoma; Proton pump inhibitor.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Moayyedi P, El-Serag HB. Current status of chemoprevention in Barrett’s esophagus. Gastrointest Endosc Clin N Am. 2021;31(1):117–30. https://doi.org/10.1016/j.giec.2020.08.008 . - DOI - PubMed
    1. Barrett NR. Chronic peptic ulcer of the oesophagus and “oesophagitis.” Br J Surg. 1950;38(150):175–82. https://doi.org/10.1002/bjs.18003815005 . - DOI - PubMed
    1. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med. 2004;164(14):1482–8. https://doi.org/10.1001/archinte.164.14.1482 . - DOI - PubMed
    1. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–6. https://doi.org/10.1136/gutjnl-2011-300730 . - DOI - PubMed
    1. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127(1):310–30. https://doi.org/10.1053/j.gastro.2004.04.010 . - DOI - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources